Protein coronas could help nanomedicines navigate the blood-brain barrier
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Oct-2026 04:16 ET (30-Oct-2026 08:16 GMT/UTC)
Nanomedicines often acquire a protein corona in the bloodstream before reaching the brain. A new Perspective in Science Bulletin argues that this evolving layer should be engineered as a programmable interface that can guide recognition, transcytosis and release across the blood-brain barrier.
A large real-world clinical trial published in Nature Medicine has found that a generative AI-powered support tool used to support frontline clinicians was safe and improved the quality of clinical decision-making but did not significantly change short-term patient outcomes.
Infected wounds pose a significant medical challenge, often leading to delayed healing and complications due to bacterial biofilms and excessive inflammation. A key characteristic of these infection sites is an acidic microenvironment. Scientists have now engineered a smart nanoplatform that uses this acidity as a trigger to release a potent combination of therapeutic agents directly at the wound site.
In an article appearing in the journal Biomedical Analysis, researchers from Sun Yat-sen University describe the development of a novel nanocomposite, SH@ZIF-8/AgNPs. This platform consists of a porous carrier called a zeolitic imidazolate framework-8 (ZIF-8), which is loaded with shikonin (SH), a natural compound with anti-inflammatory and antioxidant properties. The surface of this carrier is then decorated with silver nanoparticles (AgNPs), which are well-known for their broad-spectrum antibacterial activity. The design enables the encapsulation of a high concentration of shikonin within a stable structure.